See more : East Side Games Group Inc. (EAGR.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Hillstream BioPharma, Inc. (HILS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hillstream BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- LG HelloVision Corp. (037560.KS) Income Statement Analysis – Financial Results
- GuestLogix Inc. (GUESF) Income Statement Analysis – Financial Results
- Sentry Select Primary Metals Corp. (PME.TO) Income Statement Analysis – Financial Results
- Gallant Micro. Machining Co., LTD. (6640.TWO) Income Statement Analysis – Financial Results
- WRIT Media Group, Inc. (WRIT) Income Statement Analysis – Financial Results
Hillstream BioPharma, Inc. (HILS)
About Hillstream BioPharma, Inc.
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.56M | 2.28M | 1.84M | 847.27K | 368.73K |
| General & Administrative | 5.90M | 4.60M | 1.37M | 671.88K | 625.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.90M | 4.60M | 1.37M | 671.88K | 625.81K |
| Other Expenses | 0.00 | 0.00 | 1.83M | -362.49K | -26.46K |
| Operating Expenses | 9.46M | 6.88M | 3.21M | 1.52M | 994.54K |
| Cost & Expenses | 9.46M | 6.88M | 3.21M | 1.52M | 994.54K |
| Interest Income | 152.63K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -16.51K | 1.59M | 831.28K | 246.53K | 75.07K |
| Depreciation & Amortization | 167.90K | 1.57B | 1.83M | -73.29K | 402.95K |
| EBITDA | -9.46M | -6.88M | -1.38M | -1.88M | -1.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.46M | -6.88M | -3.21M | -1.81M | -1.42M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 136.13K | -1.59M | 1.00M | -609.02K | -101.53K |
| Income Before Tax | -9.32M | -8.47M | -2.21M | -2.42M | -1.53M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 831.28K | -42.67K | -354.33K |
| Net Income | -9.32M | -8.47M | -3.04M | -2.37M | -1.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.14 | -0.75 | -0.30 | -0.21 | -0.10 |
| EPS Diluted | -7.14 | -0.75 | -0.30 | -0.21 | -0.10 |
| Weighted Avg Shares Out | 1.31M | 11.23M | 10.30M | 11.23M | 11.23M |
| Weighted Avg Shares Out (Dil) | 1.31M | 11.23M | 10.30M | 11.23M | 11.23M |
Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
4 Penny Stocks Up Big With The Stock Market Down Today; Time To Buy?
The Stock Market is Down Today: Here's Why & 3 Penny Stocks To Watch
Source: https://incomestatements.info
Category: Stock Reports